Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for cardiac disorders

a biomarker and cardiac disease technology, applied in the field of methods, assays and kits, can solve the problems of limited experimental evidence concerning direct translational action of uorfs upon, evidence of uorf-derived peptides, and the cost of increasing the number, so as to improve the sensitivity and false positive performance of cardiac troponin, and improve the sensitivity and false positive performance

Inactive Publication Date: 2018-06-07
UPSTREAM MEDICAL TECH LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The TnTuORF peptide demonstrates utility in predicting and diagnosing cardiac disorders beyond myocardial infarction, improving the sensitivity and reducing false positives of cardiac troponin assays, and providing insights into treatment responsiveness.

Problems solved by technology

These assays have resulted in major improvements in time to diagnosis of myocardial infarction (MI), but this has come at the cost of increasing numbers of patients who have elevated levels of troponin above 99th percentile guidelines, but do not in fact have MI (Reichlin et al.
In mammalian cells there is limited experimental evidence concerning direct translational actions of uORFs upon cellular function and there is no evidence that uORF-derived peptides are present in the circulation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for cardiac disorders
  • Biomarker for cardiac disorders
  • Biomarker for cardiac disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

nd Materials

Chemicals

[0190]Synthetic human TnTuORF, TnTuORF(Tyr), TnTuORF(Cys) and amino acids 1-7 of the signal peptide of vesicular integral membrane protein 36 (VIP36sp(1-7)) were synthesised by Mimotopes (Melbourne, Australia) at greater than 95% purity by mass spectrometry and high performace liquid chromatography (HPLC). All other synthetic or purified proteins were purchased from Hytest (Turku, FI), Peptide Institute (Osaka, Japan) or Sigma-Aldrich (St Louis, USA).

Human TnTuORF Assay Development

[0191]Assessment of the 5′ region upstream of the major open reading frame of human cardiac troponin T (NCBI Accession NG_007556) identified a putative 12 amino acid peptide (full amino acid sequence MAPEGWVIVVIS; SEQ ID NO:1) encoded 1,512 bp upstream of the major open reading frame (ORF) initiation site, with a Kozak score of +2 and a high likelihood of being efficiently translated (FIG. 1). This sequence was not seen in fast (NCBI Accession NG_013085) or slow (NCBI Accession NG_0118...

example 2

ation of Endogenous TnTuORF in Human Plasma

[0199]Polyclonal antibody r244 directed towards the amino terminus of TnTuORF yielded a sensitive, specific radioimmunoassay (FIG. 2), with a mean zero binding of 31±3%, sample detection limit of 26±6 pg / mL, ED50 of 458±105 pg / mL and a working range of 130-3900 pg / mL in which the intra-assay coefficient of variation (CV) was 3-EDTA and that it diluted in parallel with the synthetic standard curve (FIG. 2). Immunoreactive TnTuORF levels in normal human venous plasma (mean±SD) were 725±340 pg / mL (range 273-2260 pg / mL, 99th percentile of upper limit of normal range=1885 pg / mL); immunoreactivity was detected in every sample. TnTuORF concentrations were significantly higher in men (825±403 pg / mL vs. 666±285 pg / mL, P=0.018) and had a significant biochemical correlation only with plasma creatinine (r=0.201, P=0.036, FIG. 3). Concomitant hsTnT levels, age, blood pressures and BMI had no significant association with TnTuORF. Corresponding hsTnT leve...

example 3

ctive TnTuORF Release into the Circulation

[0200]The form of TnT used for the diagnosis of MI is thought to be cardiac specific (Thygessen et al. (2012) Circulation 126:2020-2035). In line with this, Applicants anticipated that TnTuORF levels would be higher in blood draining the heart (i.e. in cardiac coronary sinus samples) than in blood supplying the heart (i.e. arterial samples). Coronary sinus plasma tended to contain higher concentrations of immunoreactive TnTuORF, compared with simultaneously drawn arterial plasma samples (978.2±118.1 pg / mL vs. 908.7±88.9 pg / mL, Mean±SD, P=0.472, FIG. 4). However, elevated venous levels of TnTuORF were also observed across the hepatic vein, whereas there tended to be reduced TnTuORF levels across the femoral vein. In comparison, hsTnT levels were significantly elevated in cardiac coronary sinus plasma samples (13.1±2.7 pg / mL vs. 10.1±1.8 pg / mL, P=0.019). Renal venous levels of hsTnT were significantly lower compared with arterial levels (8.6±1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates generally to assays, methods and kits for the prognosis and / or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating troponin biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.

Description

STATEMENT REGARDING SEQUENCE LISTING[0001]The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 720125_402USPC_SEQUENCE_LISTING.txt. The text file is 1.1 KB, was created on Sep. 7, 2017, and is being submitted electronically via EFS-Web.TECHNICAL FIELD[0002]The present invention relates generally to methods, assays and kits for the prognosis and / or diagnosis of cardiac disorders.BACKGROUND OF THE INVENTION[0003]The following includes information that may be useful in understanding the present invention. It is not an admission that any of the information, publications or documents specifically or implicitly referred to or referenced herein is prior art, or essential, to the presently described or claimed inventions. All publications and patents mentioned in this specification are incorporated herein by referen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68C07K14/47C07K16/18
CPCG01N2800/52G01N2800/50G01N33/6893C07K14/4716C07K16/18G01N33/6887C07K2317/33C07K2317/34G01N2333/4712G01N2800/32
Inventor LEE, JACQUELINE AMANDAPEMBERTON, CHRISTOPHER JOSEPH
Owner UPSTREAM MEDICAL TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com